- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06412822
Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone
Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone, Cross-section, Non-drug Clinical Study-Analysis of Biological Fluids (Residual Human Body Material (RHBM)): STONET's Project
Neutrophils are first responders to any kind of threat the body faces: infection, severe trauma, cancer, surgery... They produce the cytokines, induct oxidative stress and de-granulate toxic proteins to kill pathogens. However the new mechanism related to the neutrophil extracellular traps release has been recognized as a new way of cell necrosis and has been called a NETosis.
NETosis is a hugely important new mechanism of human immune responses also described in various forms of acute kidney injury (ischemic, toxic, autoimmune). In certain kidney diseases, neutrophils release NETs and induce cell necrosis. Whether neutrophils die along with NET release, and if they do die, remains under study and is most likely context dependent. Extracellular traps (ETs) can be released also by macrophages. The ETs formation as well as macrophages extracellular traps (MET's) especially in kidney disease are cytotoxic and elicit inflammation, contributing to necro-inflammation of the early-injury phase of acute tubular necrosis in anti-neutrophil cytoplasmic antibody-related renal vasculitis, anti-glomerular basement membrane disease, lupus nephritis. Finally, acute kidney injury-related releases of dying renal cells or ETs promote organ injuries - for example, acute respiratory distress syndrome. According to the recent review the term 'NET formation' has been proposed as a better term to use instead of 'NETosis'. The formation of neutrophil extracellular traps (NETs) has been recently recognized as a unique modality of pathogen fixation (sticky extracellular chromatin) and pathogen killing (cytotoxic histones and proteases) during host immune responses, as well as collateral tissue damage.
Histones are potent mediators of injury in various cells. Indeed, extracellular histone induce microvascular endothelial cells and renal epithelial cells death in vitro, forms the pores that disrupt cell integrity and induce the cytolysis by their capacity of binding with membrane phospholipids and activation of inflammasome in the kidney leading to auto-entrainment of inflammation.
The activation of inflammation has been demonstrated in the experimental model of crystalline nephropathy related to the uncontrolled oxalate urinary excretion. Inhibition of inflammasome activation has been related with the preservation of kidney function. In patients with kidney stone disease the presence of crystals in the urine has been demonstrated to induce tubular epithelial cells injury that can theoretically trigger the NET's or MET's release and tissue inflammation.
NETs are now increasingly described as new targets for therapies, however largely under-estimated.
The role of release of ETs from neutrophils and macrophages during the kidney stone disease has never been studied in urine but the neutrophil extracellular trap (NET) formation-NETosis - was found significantly increased in the papillae of patients with brushite stones compared with CaOx stones.
The key objectives of this study are:
- to assess NET/MET's excretion in the urine as a non-invasive method of NET/MET'osis measurement in patients with kidney diseases as a new biomarker of early stage of cells damages reflecting kidney injury occurring in patients with uncontrolled stones and other renal diseases;
- to compare the NET/MET's concentrations in the urine with those in plasma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Agnieszka POZDZIK
- Phone Number: 3224752639
- Email: Agnieszka.POZDZIK@chu-brugmann.be
Study Locations
-
-
-
Brussel, Belgium, 1020
- Recruiting
- CHU Brugmann
-
Contact:
- Agnieszka Pozdzik, MD,PhD
- Phone Number: +32 (0)2 4752639
- Email: agnieszka.pozdzik@chu-brugmann.be
-
Principal Investigator:
- Agnieszka Pozdzik, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with acute and/or chronic kidney disease, with stones or without stones, ambulatory or hospitalized in CHU Brugmann Brugmann.
Exclusion Criteria:
- Malignancy or treatment for malignancy within 12 months prior to Screening with the exception of localized basal cell or squamous cell skin cancer. Note: Subjects whose malignancy is in remission and who are on a stable dose of chronic suppressive or maintenance therapy are not excluded.
- Psychological illness or condition, interfering with the patient's compliance or ability to understand the requirements of the study.
- Participation in another clinical trial.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
STONE group
Adult subjects with kidney stones disease
|
Blood sampling
Urine sampling
|
NON STONE group
Control group: patients with acute and/or chronic kidney disease (CKD) without stones
|
Blood sampling
Urine sampling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neutrophil extracellular traps (NETs) excretion in 24h urine collection
Time Frame: 24 hours
|
Assessment of NET excretion in 24h urine collection
|
24 hours
|
Neutrophil extracellular traps (NETs) excretion in fasting urine
Time Frame: 24 hours
|
Assessment of NET excretion in fasting urine
|
24 hours
|
Neutrophil extracellular traps (NETs) excretion in 2e morning urine
Time Frame: 24 hours
|
Assessment of NET excretion in 2e morning urine
|
24 hours
|
Macrophages extracellular traps (MET's) excretion in 24h urine collection
Time Frame: 24 hours
|
Assessment of MET's in 24h urine collection
|
24 hours
|
Macrophages extracellular traps (MET's) excretion in fasting urine
Time Frame: 24 hours
|
Assessment of MET's in fasting urine
|
24 hours
|
Macrophages extracellular traps (MET's) excretion in 2e morning urine
Time Frame: 24 hours
|
Assessment of MET's in 2e morning urine
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neutrophil extracellular traps (NETs) plasma levels
Time Frame: 24 hours
|
Neutrophil extracellular traps (NETs) plasma levels
|
24 hours
|
Macrophages extracellular traps (MET's) plasma levels
Time Frame: 24 hours
|
Macrophages extracellular traps (MET's) plasma levels
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Agnieszka POZDZIK, CHU Brugmann
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STONET's
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stone
-
Washington University School of MedicineRecruiting
-
Société Internationale d'UrologieCompletedStone Ureter | Stone, Kidney | Stone;RenalUnited States, China, Korea, Republic of, Malaysia, Saudi Arabia, Greece, India, Indonesia, Iran, Islamic Republic of, Iraq, Kenya, Romania, South Africa, Taiwan, Turkey
-
Wake Forest University Health SciencesCogenix Medical CorporationWithdrawnKidney Stone | Renal Stone | Ureter StoneUnited States
-
Advance Shockwave Technology GmbHUnknownKidney StonesUnited States
-
Mansoura UniversityCompletedUrologic Diseases | Stone, Kidney | Stone, Urinary | ESWL | Radiolucent Calculus of Urinary Tract | DissolutionEgypt
-
University of British ColumbiaActive, not recruiting
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
VA New York Harbor Healthcare SystemCompletedKidney StonesUnited States
-
Selcuk UniversityThe Scientific and Technological Research Council of TurkeySuspendedKidney StonesTurkey
-
Mansoura UniversityCompleted
Clinical Trials on Blood sampling
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance